P-Toluenesulfonamide - Beijing Vision Drugs Development
Latest Information Update: 21 Aug 2015
At a glance
- Originator Beijing Vision Drugs Development
- Class Antineoplastics; Small molecules; Sulfonamides; Toluenes
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Breast cancer; Liver cancer; Lung cancer; Solid tumours
Most Recent Events
- 21 Aug 2015 Phase III development completed in China